PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.


Journal

The EMBO journal
ISSN: 1460-2075
Titre abrégé: EMBO J
Pays: England
ID NLM: 8208664

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 26 06 2023
accepted: 23 01 2024
revised: 22 01 2024
medline: 18 3 2024
pubmed: 16 2 2024
entrez: 15 2 2024
Statut: ppublish

Résumé

Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a tailored therapy. Moreover, the identification of such vulnerabilities is of interest for targeting BRCA2;p53-deficient tumors that have acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) through loss of PARG expression. Here, by performing whole-genome CRISPR/Cas9 drop-out screens, we identify various genes involved in DNA repair to be essential for the survival of PARG;BRCA2;p53-deficient cells. In particular, our findings reveal EXO1 and FEN1 as major synthetic lethal interactors of PARG loss. We provide evidence for compromised replication fork progression, DNA single-strand break repair, and Okazaki fragment processing in PARG;BRCA2;p53-deficient cells, alterations that exacerbate the effects of EXO1/FEN1 inhibition and become lethal in this context. Since this sensitivity is dependent on BRCA2 defects, we propose to target EXO1/FEN1 in PARPi-resistant tumors that have lost PARG activity. Moreover, EXO1/FEN1 targeting may be a useful strategy for enhancing the effect of PARG inhibitors in homologous recombination-deficient tumors.

Identifiants

pubmed: 38360994
doi: 10.1038/s44318-024-00043-2
pii: 10.1038/s44318-024-00043-2
pmc: PMC10943112
doi:

Substances chimiques

Tumor Suppressor Protein p53 0
Poly(ADP-ribose) Polymerase Inhibitors 0
Glycoside Hydrolases EC 3.2.1.-
FEN1 protein, human EC 3.1.11.-
Flap Endonucleases EC 3.1.-
EXO1 protein, human EC 3.1.-
Exodeoxyribonucleases EC 3.1.-
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1015-1042

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
ID : 310030_179360
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
ID : P1BEP3_195482
Organisme : EC | European Research Council (ERC)
ID : ERC-2019-AdG-883877
Organisme : Krebsliga Schweiz (Swiss Cancer League)
ID : KFS-5519-02-2022
Organisme : Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
ID : 2019.069.1
Organisme : KWF Kankerbestrijding (DCS)
ID : KWF 2017-61169
Organisme : KWF Kankerbestrijding (DCS)
ID : KWF 2020-12894
Organisme : Grantová Agentura České Republiky (GAČR)
ID : 22-00885S

Informations de copyright

© 2024. The Author(s).

Références

BMC Bioinformatics. 2017 Nov 29;18(1):529
pubmed: 29187165
Nat Genet. 2001 Dec;29(4):418-25
pubmed: 11694875
Mol Cell. 2019 Mar 7;73(5):885-899.e6
pubmed: 30686591
J Cell Biol. 2014 Jun 9;205(5):613-9
pubmed: 24914234
Nat Genet. 2000 Jun;25(2):217-22
pubmed: 10835641
Mol Cell. 2024 Feb 15;84(4):659-674.e7
pubmed: 38266640
Genome Res. 2015 Aug;25(8):1147-57
pubmed: 26063738
Nat Commun. 2012 Jun 06;3:878
pubmed: 22673905
Nucleic Acids Res. 2014 Dec 16;42(22):e168
pubmed: 25300484
Methods Enzymol. 2017;591:55-82
pubmed: 28645379
Cell Rep. 2023 May 30;42(5):112538
pubmed: 37209095
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Sci Adv. 2019 Apr 10;5(4):eaav4340
pubmed: 30989114
Nat Commun. 2013;4:2164
pubmed: 23917065
DNA Repair (Amst). 2015 Aug;32:10-16
pubmed: 25963443
PLoS One. 2017 Jun 19;12(6):e0179278
pubmed: 28628639
Cancer Cell. 2019 Mar 18;35(3):519-533.e8
pubmed: 30889383
Nat Rev Clin Oncol. 2021 Dec;18(12):773-791
pubmed: 34285417
Prog Biophys Mol Biol. 2021 Aug;163:160-170
pubmed: 33524442
Nat Struct Mol Biol. 2012 May 20;19(6):653-6
pubmed: 22609859
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioessays. 2004 Aug;26(8):882-93
pubmed: 15273990
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Clin Cancer Res. 2008 Jun 15;14(12):3916-25
pubmed: 18559613
Genes Dev. 2020 Mar 1;34(5-6):360-394
pubmed: 32029455
Mol Cell Biol. 2007 Aug;27(15):5597-605
pubmed: 17548475
J Cell Sci. 2013 Oct 1;126(Pt 19):4414-23
pubmed: 23868975
Nat Chem Biol. 2016 Oct;12(10):815-21
pubmed: 27526030
Nat Struct Mol Biol. 2022 Apr;29(4):329-338
pubmed: 35332322
Nat Commun. 2019 Dec 11;10(1):5654
pubmed: 31827085
Cell Rep. 2016 Oct 18;17(4):1193-1205
pubmed: 27760321
DNA Repair (Amst). 2018 Nov;71:172-176
pubmed: 30177437
Ann Oncol. 2021 Jan;32(1):103-112
pubmed: 33091561
Nat Commun. 2019 Mar 12;10(1):1182
pubmed: 30862789
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8241-6
pubmed: 11459959
Nat Commun. 2020 Jul 7;11(1):3391
pubmed: 32636369
Mol Biol Cell. 2019 Sep 15;30(20):2584-2597
pubmed: 31390283
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Methods Mol Biol. 2016;1470:49-73
pubmed: 27581284
Biosci Rep. 2015 Apr 25;35(3):
pubmed: 26182368
Clin Cancer Res. 2013 Oct 1;19(19):5485-93
pubmed: 23922302
Mol Cell. 2018 Jul 19;71(2):319-331.e3
pubmed: 29983321
Genome Biol. 2014;15(12):554
pubmed: 25476604
Chromosoma. 2014 Mar;123(1-2):79-90
pubmed: 24162931
Mol Cell. 2018 Jun 7;70(5):801-813.e6
pubmed: 29804829
Front Cell Dev Biol. 2020 Sep 09;8:564601
pubmed: 33015058
Methods Enzymol. 2006;409:410-25
pubmed: 16793415
Genes Dev. 2005 Sep 1;19(17):1951-67
pubmed: 16140981
EMBO J. 2013 May 2;32(9):1225-37
pubmed: 23481255
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Nat Commun. 2017 Oct 16;8(1):860
pubmed: 29038425
J Biol Chem. 2006 Jan 13;281(2):705-13
pubmed: 16278211
J Pathol. 2013 Feb;229(3):422-9
pubmed: 23165508
PLoS One. 2010 Apr 08;5(4):e10089
pubmed: 20386692
Annu Rev Cancer Biol. 2018 Mar;2:313-336
pubmed: 30345412
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Mol Cell Biol. 2015 Mar;35(5):856-65
pubmed: 25535335
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12
pubmed: 29894693
Int J Mol Sci. 2022 Jul 29;23(15):
pubmed: 35955544
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Biochim Biophys Acta. 2014 Aug;1846(1):201-15
pubmed: 25026313
Elife. 2017 Jun 26;6:
pubmed: 28650317
Cell Death Discov. 2016 Mar 21;2:16011
pubmed: 27551505
Nature. 2011 Sep 04;477(7366):616-20
pubmed: 21892188
Cancer Discov. 2017 Sep;7(9):937-939
pubmed: 28864639
J Natl Cancer Inst. 2016 Jul 05;108(11):
pubmed: 27381626
Nature. 2008 Feb 28;451(7182):1116-20
pubmed: 18264087
J Pharmacol Exp Ther. 2014 Jun;349(3):408-16
pubmed: 24650937
PLoS One. 2011 Apr 15;6(4):e18618
pubmed: 21525980
EMBO Rep. 2006 Sep;7(9):919-26
pubmed: 16888651
ACS Chem Biol. 2016 Nov 18;11(11):3179-3190
pubmed: 27689388
Mol Oncol. 2022 Nov;16(21):3811-3827
pubmed: 35567571
J Med Chem. 2018 Dec 13;61(23):10767-10792
pubmed: 30403352

Auteurs

Christina Andronikou (C)

Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
Oncode Institute, Amsterdam, The Netherlands.
Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3088, Bern, Switzerland.

Kamila Burdova (K)

Laboratory of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic.

Diego Dibitetto (D)

Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3088, Bern, Switzerland.

Cor Lieftink (C)

Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.

Elke Malzer (E)

Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.

Hendrik J Kuiken (HJ)

Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.

Ewa Gogola (E)

Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.

Arnab Ray Chaudhuri (A)

Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015GD, Rotterdam, The Netherlands.

Roderick L Beijersbergen (RL)

Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.

Hana Hanzlikova (H)

Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Laboratory of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic.

Jos Jonkers (J)

Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. j.jonkers@nki.nl.
Oncode Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.

Sven Rottenberg (S)

Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.
Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. sven.rottenberg@unibe.ch.
Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3088, Bern, Switzerland. sven.rottenberg@unibe.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH